Gastric Neoplasms

Oncology
5
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

M&
KEYTRUDAApproved
pembrolizumab
Merck & Co.
Programmed Death Receptor-1 Blocking Antibody [EPC]intravenous2014

Competitive Landscape

5 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
1
PembrolizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03019588Terminated94Est. Jun 2021
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
ZanidatamabPhase 3Monoclonal Antibody
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
ZanidatamabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05152147Active Not Recruiting920Est. Jul 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
ASG-5MEPhase 11 trial
Active Trials
NCT01166490Completed51Est. Jul 2013
Seed Therapeutics
Seed TherapeuticsNY - New York
1 program
Identification of risk factorsN/A1 trial
Active Trials
NCT05551416RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Jazz PharmaceuticalsZanidatamab
Merck & Co.Pembrolizumab
PfizerASG-5ME
Seed TherapeuticsIdentification of risk factors

Clinical Trials (4)

Total enrollment: 1,065 patients across 4 trials

NCT05152147Jazz PharmaceuticalsZanidatamab

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Start: Dec 2021Est. completion: Jul 2027920 patients
Phase 3Active Not Recruiting
NCT03019588Merck & Co.Pembrolizumab

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Start: Feb 2017Est. completion: Jun 202194 patients
Phase 3Terminated
NCT01166490PfizerASG-5ME

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Start: Jul 2010Est. completion: Jul 201351 patients
Phase 1Completed
NCT05551416Seed TherapeuticsIdentification of risk factors

The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer

Start: Sep 2021Est. completion: Dec 2026
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,065 patients
Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)